Active, not recruitingPhase 1NCT05397496
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Intervention
- PIT565(biological)
- Enrollment
- 61 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2022 – 2026
Study locations (16)
- University Of Miami, Miami, Florida, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- The University of Kansas Clinical Research Ctr, Fairway, Kansas, United States
- Memorial Sloan Kettering Cancer Ctr, New York, New York, United States
- Oregon Health Sciences University, Portland, Oregon, United States
- Novartis Investigative Site, Ghent, Belgium
- Novartis Investigative Site, Beijing, China
- Novartis Investigative Site, Shanghai, China
- Novartis Investigative Site, Tianjin, China
- Novartis Investigative Site, Créteil, France
- Novartis Investigative Site, Marseille, France
- Novartis Investigative Site, Tel Aviv, Israel
- Novartis Investigative Site, Reggio Emilia, RE, Italy
- Novartis Investigative Site, Kashiwa, Chiba, Japan
- Novartis Investigative Site, Singapore, Singapore
- +1 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05397496 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University